BIOTRON LIMITED - Announcements

Market Cap $18.04M Add to my watchlist

Healthcare Biotechnology

Biotron Limited is an Australia-based biotechnology company. The Company is primarily... Biotron Limited is an Australia-based biotechnology company. The Company is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Company’s clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

BIT	Phase 2 Hepatitis C Trial Success	PRICE SENSITIVE	17/03/16	26.86KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/16	107.47KB	Share
BIT	BIT225 MAY HAVE A BROADER ROLE IN LIMITING HIV-1 INFECTION	PRICE SENSITIVE	18/02/16	36.42KB	Share
BIT	BIOTRON COMPOUNDS TESTED FOR ACTIVITY AGAINST ZIKA VIRUS	PRICE SENSITIVE	16/02/16	22.68KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	15/01/16	22.71KB	Share
BIT	Appendix 3B		15/01/16	59.08KB	Share
BIT	BIOTRON LIMITED PRESENTS AT BIOTECH SHOWCASE 2016		12/01/16	3.12MB	Share
BIT	POTENTIAL ERADICATION OF HIV RESEVOIRS DATA PUBLISHED		03/12/15	25.4KB	Share
BIT	Grant of Options and Appendices 3B and 3Y		25/11/15	111.57KB	Share
BIT	Results of Meeting		24/11/15	29.07KB	Share
BIT	AGM Presentation		24/11/15	1.91MB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	22/10/15	37.74KB	Share
BIT	Annual Report, Governance Statement and Notice of AGM		21/10/15	757.9KB	Share
BIT	Change of Director's Interest Notice		15/10/15	38.57KB	Share
BIT	Presentation to Investors		06/10/15	524.59KB	Share
BIT	Letter to Shareholders		06/10/15	139.7KB	Share
BIT	INTERIM HCV GENOTYPE 3 DATA FROM BIT225-008 STUDY	PRICE SENSITIVE	30/09/15	31.61KB	Share
BIT	Annual Report to Shareholders	PRICE SENSITIVE	28/08/15	363.33KB	Share
BIT	Investor Presentation		20/08/15	1.06MB	Share
BIT	Letter to Shareholders		28/07/15	247.39KB	Share
BIT	Cash Flow Report	PRICE SENSITIVE	27/07/15	47.21KB	Share
BIT	SPP Completed. Appendices 3B and 3Y.		15/07/15	157.81KB	Share
BIT	Independent review supports development of BIT225	PRICE SENSITIVE	06/07/15	25.16KB	Share
BIT	Appendix 3B		03/07/15	111.39KB	Share
BIT	Appendix 3B		23/06/15	121.63KB	Share
BIT	Share Purchase Plan and Placement to Raise $4.0 Million	PRICE SENSITIVE	18/06/15	339.09KB	Share
BIT	Trading Halt	PRICE SENSITIVE	16/06/15	42.19KB	Share
BIT	Presentation to Investors		28/05/15	1.78MB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/15	37.76KB	Share
BIT	R&D Tax Incentive	PRICE SENSITIVE	21/04/15	48.72KB	Share
BIT	Update on Phase 2 Trial and IND Progress	PRICE SENSITIVE	17/04/15	40.79KB	Share
BIT	Change of Director's Interest Notice		05/03/15	38.62KB	Share
BIT	Appendix 3B		27/02/15	59.07KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/15	112.08KB	Share
BIT	Response to ASX price query	PRICE SENSITIVE	26/02/15	111.4KB	Share
BIT	Appendix 3B		03/02/15	59.07KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	21/01/15	37.77KB	Share
BIT	BIOTRON LIMITED PRESENTS AT BIOTECH SHOWCASE 2015		13/01/15	39.26KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	08/01/15	117.33KB	Share
BIT	Appendix 3B		19/12/14	59.1KB	Share
BIT	Details of Share Registry Address		10/12/14	18.99KB	Share
BIT	Presentation to Investors		04/12/14	2.27MB	Share
BIT	Enrolment of Phase 2 Hepatitis C Trial of BIT225 Completed	PRICE SENSITIVE	03/12/14	26.74KB	Share
BIT	Appendix 3B		03/12/14	59.09KB	Share
BIT	Change of Director's Interest Notice		20/11/14	39.09KB	Share
BIT	Results of Meeting		13/11/14	28.54KB	Share
BIT	Chairman's Address to Shareholders		13/11/14	2.59MB	Share
BIT	Change of Director's Interest Notice		12/11/14	58.95KB	Share
BIT	Fully Underwritten Rights Issue Closes Oversubscribed		05/11/14	84.35KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/14	37.7KB	Share
BIT	Appendix 3B		15/10/14	71.2KB	Share
BIT	Rights Issue Prospectus	PRICE SENSITIVE	15/10/14	1.69MB	Share
BIT	Fully Underwritten Rights Issue and Investor Presentation	PRICE SENSITIVE	15/10/14	2.31MB	Share
BIT	Annual Report and Notice of AGM		14/10/14	584.46KB	Share
BIT	Trading halt	PRICE SENSITIVE	13/10/14	46.2KB	Share
BIT	BIT225 TRIAL RESULTS SHOW EFFECTIVE CURE OF HEPATITIS C	PRICE SENSITIVE	10/10/14	55.29KB	Share
BIT	Annual Report to Shareholders	PRICE SENSITIVE	28/08/14	388.98KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/07/14	37.75KB	Share
BIT	BIT225 Reverses HIV-Induced Impairment of the Immune System	PRICE SENSITIVE	23/07/14	792.76KB	Share
BIT	Response to ASX price query	PRICE SENSITIVE	06/06/14	78.98KB	Share
BIT	Presentation to Investors		27/05/14	1.33MB	Share
BIT	BIT225 HCV Trial Update - Thailand	PRICE SENSITIVE	23/05/14	41.72KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/14	73.92KB	Share
BIT	$1.7 Million R&D Tax Incentive Refund	PRICE SENSITIVE	04/04/14	49.09KB	Share
BIT	Letter to Shareholders		31/03/14	240.01KB	Share
BIT	Update on BIT225 HCV Program	PRICE SENSITIVE	11/03/14	54KB	Share
BIT	BIT225 HIV/HCV TRIAL PATIENTS VIRUS FREE AT SIX MONTHS	PRICE SENSITIVE	06/03/14	54.55KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	21/02/14	116.45KB	Share
BIT	Key USA Patent Allowed for Biotron's BIT225	PRICE SENSITIVE	13/02/14	54.23KB	Share
BIT	Response to ASX query	PRICE SENSITIVE	23/01/14	86.74KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	21/01/14	37.71KB	Share
BIT	BIOTRON TO PRESENT AT BIOTECH SHOWCASE 2014		14/01/14	52.89KB	Share
BIT	Presentation of HIV Data at HIV Persistence Meeting	PRICE SENSITIVE	05/12/13	282.82KB	Share
BIT	Independent Research Validates Biotron HCV Drug Candidate	PRICE SENSITIVE	27/11/13	53.94KB	Share
BIT	Ethics Approval for Three Month HCV Trial	PRICE SENSITIVE	21/11/13	59.15KB	Share
BIT	Final Director's Interest Notice		08/11/13	24.57KB	Share
BIT	Results of Meeting		08/11/13	28.75KB	Share
BIT	Presentation to Annual General Meeting		08/11/13	2.88MB	Share
BIT	HCV/HIV Trial Data Presented to International Conference	PRICE SENSITIVE	06/11/13	822.72KB	Share
BIT	Biotron to Present at Australia Biotech Invest 2013		28/10/13	1.65MB	Share
BIT	ANTIVIRAL ACTIVITY ENHANCED IN HIV/HCV GENOTYPE 3 PATIENTS	PRICE SENSITIVE	25/10/13	49.49KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	21/10/13	37.66KB	Share
BIT	Annual Report and Notice of Annual General Meeting		10/10/13	612.15KB	Share
BIT	Annual Report to shareholders	PRICE SENSITIVE	28/08/13	240.81KB	Share
BIT	Letter to Shareholders		16/08/13	212.96KB	Share
BIT	BIT225 Capsule Formulation Trial Completed	PRICE SENSITIVE	14/08/13	93.96KB	Share
BIT	Patient Enrolment in Phase 2 Co-Infected Study Completed	PRICE SENSITIVE	31/07/13	108.16KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	26/07/13	37.72KB	Share
BIT	Presentation of HIV Trial Data to International AIDS Society	PRICE SENSITIVE	01/07/13	2.81MB	Share
BIT	PRESENTATION AT ASIA BIOTECH INVEST 2013 - HONG KONG		05/06/13	1.64MB	Share
BIT	R&D Tax Incentive Refund	PRICE SENSITIVE	31/05/13	33.21KB	Share
BIT	PRESENTATION OF HIV DATA AT INTERNATIONAL AIDS SOCIETY		30/05/13	53.55KB	Share
BIT	Presentation at European Liver Conference		01/05/13	48.68KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/13	37.71KB	Share
BIT	CEO Presentation at the 2013 BIO International Convention		26/04/13	1.67MB	Share
BIT	Letter to Shareholders		10/04/13	212.75KB	Share
BIT	HIV TRIAL VALIDATES NOVEL DRUG MECHANISM	PRICE SENSITIVE	19/03/13	54.49KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/13	173.99KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	17/01/13	37.7KB	Share
BIT	Biotron Completes Clinical Stage of HIV Clinical Trial	PRICE SENSITIVE	14/12/12	49.29KB	Share

BIT Phase 2 Hepatitis C Trial Success
17/03/16	PRICE SENSITIVE	26.86KB	Share
BIT Half Yearly Report and Accounts
26/02/16	PRICE SENSITIVE	107.47KB	Share
BIT BIT225 MAY HAVE A BROADER ROLE IN LIMITING HIV-1 INFECTION
18/02/16	PRICE SENSITIVE	36.42KB	Share
BIT BIOTRON COMPOUNDS TESTED FOR ACTIVITY AGAINST ZIKA VIRUS
16/02/16	PRICE SENSITIVE	22.68KB	Share
BIT Appendix 4C - quarterly
15/01/16	PRICE SENSITIVE	22.71KB	Share
BIT Appendix 3B
15/01/16		59.08KB	Share
BIT BIOTRON LIMITED PRESENTS AT BIOTECH SHOWCASE 2016
12/01/16		3.12MB	Share
BIT POTENTIAL ERADICATION OF HIV RESEVOIRS DATA PUBLISHED
03/12/15		25.4KB	Share
BIT Grant of Options and Appendices 3B and 3Y
25/11/15		111.57KB	Share
BIT Results of Meeting
24/11/15		29.07KB	Share
BIT AGM Presentation
24/11/15		1.91MB	Share
BIT Appendix 4C - quarterly
22/10/15	PRICE SENSITIVE	37.74KB	Share
BIT Annual Report, Governance Statement and Notice of AGM
21/10/15		757.9KB	Share
BIT Change of Director's Interest Notice
15/10/15		38.57KB	Share
BIT Presentation to Investors
06/10/15		524.59KB	Share
BIT Letter to Shareholders
06/10/15		139.7KB	Share
BIT INTERIM HCV GENOTYPE 3 DATA FROM BIT225-008 STUDY
30/09/15	PRICE SENSITIVE	31.61KB	Share
BIT Annual Report to Shareholders
28/08/15	PRICE SENSITIVE	363.33KB	Share
BIT Investor Presentation
20/08/15		1.06MB	Share
BIT Letter to Shareholders
28/07/15		247.39KB	Share
BIT Cash Flow Report
27/07/15	PRICE SENSITIVE	47.21KB	Share
BIT SPP Completed. Appendices 3B and 3Y.
15/07/15		157.81KB	Share
BIT Independent review supports development of BIT225
06/07/15	PRICE SENSITIVE	25.16KB	Share
BIT Appendix 3B
03/07/15		111.39KB	Share
BIT Appendix 3B
23/06/15		121.63KB	Share
BIT Share Purchase Plan and Placement to Raise $4.0 Million
18/06/15	PRICE SENSITIVE	339.09KB	Share
BIT Trading Halt
16/06/15	PRICE SENSITIVE	42.19KB	Share
BIT Presentation to Investors
28/05/15		1.78MB	Share
BIT Appendix 4C - quarterly
24/04/15	PRICE SENSITIVE	37.76KB	Share
BIT R&D Tax Incentive
21/04/15	PRICE SENSITIVE	48.72KB	Share
BIT Update on Phase 2 Trial and IND Progress
17/04/15	PRICE SENSITIVE	40.79KB	Share
BIT Change of Director's Interest Notice
05/03/15		38.62KB	Share
BIT Appendix 3B
27/02/15		59.07KB	Share
BIT Half Yearly Report and Accounts
27/02/15	PRICE SENSITIVE	112.08KB	Share
BIT Response to ASX price query
26/02/15	PRICE SENSITIVE	111.4KB	Share
BIT Appendix 3B
03/02/15		59.07KB	Share
BIT Appendix 4C - quarterly
21/01/15	PRICE SENSITIVE	37.77KB	Share
BIT BIOTRON LIMITED PRESENTS AT BIOTECH SHOWCASE 2015
13/01/15		39.26KB	Share
BIT Response to ASX Price Query
08/01/15	PRICE SENSITIVE	117.33KB	Share
BIT Appendix 3B
19/12/14		59.1KB	Share
BIT Details of Share Registry Address
10/12/14		18.99KB	Share
BIT Presentation to Investors
04/12/14		2.27MB	Share
BIT Enrolment of Phase 2 Hepatitis C Trial of BIT225 Completed
03/12/14	PRICE SENSITIVE	26.74KB	Share
BIT Appendix 3B
03/12/14		59.09KB	Share
BIT Change of Director's Interest Notice
20/11/14		39.09KB	Share
BIT Results of Meeting
13/11/14		28.54KB	Share
BIT Chairman's Address to Shareholders
13/11/14		2.59MB	Share
BIT Change of Director's Interest Notice
12/11/14		58.95KB	Share
BIT Fully Underwritten Rights Issue Closes Oversubscribed
05/11/14		84.35KB	Share
BIT Appendix 4C - quarterly
31/10/14	PRICE SENSITIVE	37.7KB	Share
BIT Appendix 3B
15/10/14		71.2KB	Share
BIT Rights Issue Prospectus
15/10/14	PRICE SENSITIVE	1.69MB	Share
BIT Fully Underwritten Rights Issue and Investor Presentation
15/10/14	PRICE SENSITIVE	2.31MB	Share
BIT Annual Report and Notice of AGM
14/10/14		584.46KB	Share
BIT Trading halt
13/10/14	PRICE SENSITIVE	46.2KB	Share
BIT BIT225 TRIAL RESULTS SHOW EFFECTIVE CURE OF HEPATITIS C
10/10/14	PRICE SENSITIVE	55.29KB	Share
BIT Annual Report to Shareholders
28/08/14	PRICE SENSITIVE	388.98KB	Share
BIT Appendix 4C - quarterly
24/07/14	PRICE SENSITIVE	37.75KB	Share
BIT BIT225 Reverses HIV-Induced Impairment of the Immune System
23/07/14	PRICE SENSITIVE	792.76KB	Share
BITResponse to ASX price query
06/06/14	PRICE SENSITIVE	78.98KB	Share
BITPresentation to Investors
27/05/14		1.33MB	Share
BITBIT225 HCV Trial Update - Thailand
23/05/14	PRICE SENSITIVE	41.72KB	Share
BITAppendix 4C - quarterly
24/04/14	PRICE SENSITIVE	73.92KB	Share
BIT$1.7 Million R&D Tax Incentive Refund
04/04/14	PRICE SENSITIVE	49.09KB	Share
BITLetter to Shareholders
31/03/14		240.01KB	Share
BITUpdate on BIT225 HCV Program
11/03/14	PRICE SENSITIVE	54KB	Share
BITBIT225 HIV/HCV TRIAL PATIENTS VIRUS FREE AT SIX MONTHS
06/03/14	PRICE SENSITIVE	54.55KB	Share
BITHalf Yearly Report and Accounts
21/02/14	PRICE SENSITIVE	116.45KB	Share
BITKey USA Patent Allowed for Biotron's BIT225
13/02/14	PRICE SENSITIVE	54.23KB	Share
BITResponse to ASX query
23/01/14	PRICE SENSITIVE	86.74KB	Share
BITAppendix 4C - quarterly
21/01/14	PRICE SENSITIVE	37.71KB	Share
BITBIOTRON TO PRESENT AT BIOTECH SHOWCASE 2014
14/01/14		52.89KB	Share
BITPresentation of HIV Data at HIV Persistence Meeting
05/12/13	PRICE SENSITIVE	282.82KB	Share
BITIndependent Research Validates Biotron HCV Drug Candidate
27/11/13	PRICE SENSITIVE	53.94KB	Share
BITEthics Approval for Three Month HCV Trial
21/11/13	PRICE SENSITIVE	59.15KB	Share
BITFinal Director's Interest Notice
08/11/13		24.57KB	Share
BITResults of Meeting
08/11/13		28.75KB	Share
BITPresentation to Annual General Meeting
08/11/13		2.88MB	Share
BITHCV/HIV Trial Data Presented to International Conference
06/11/13	PRICE SENSITIVE	822.72KB	Share
BITBiotron to Present at Australia Biotech Invest 2013
28/10/13		1.65MB	Share
BITANTIVIRAL ACTIVITY ENHANCED IN HIV/HCV GENOTYPE 3 PATIENTS
25/10/13	PRICE SENSITIVE	49.49KB	Share
BITAppendix 4C - quarterly
21/10/13	PRICE SENSITIVE	37.66KB	Share
BITAnnual Report and Notice of Annual General Meeting
10/10/13		612.15KB	Share
BITAnnual Report to shareholders
28/08/13	PRICE SENSITIVE	240.81KB	Share
BITLetter to Shareholders
16/08/13		212.96KB	Share
BITBIT225 Capsule Formulation Trial Completed
14/08/13	PRICE SENSITIVE	93.96KB	Share
BITPatient Enrolment in Phase 2 Co-Infected Study Completed
31/07/13	PRICE SENSITIVE	108.16KB	Share
BITAppendix 4C - quarterly
26/07/13	PRICE SENSITIVE	37.72KB	Share
BITPresentation of HIV Trial Data to International AIDS Society
01/07/13	PRICE SENSITIVE	2.81MB	Share
BITPRESENTATION AT ASIA BIOTECH INVEST 2013 - HONG KONG
05/06/13		1.64MB	Share
BITR&D Tax Incentive Refund
31/05/13	PRICE SENSITIVE	33.21KB	Share
BITPRESENTATION OF HIV DATA AT INTERNATIONAL AIDS SOCIETY
30/05/13		53.55KB	Share
BITPresentation at European Liver Conference
01/05/13		48.68KB	Share
BITAppendix 4C - quarterly
30/04/13	PRICE SENSITIVE	37.71KB	Share
BITCEO Presentation at the 2013 BIO International Convention
26/04/13		1.67MB	Share
BITLetter to Shareholders
10/04/13		212.75KB	Share
BITHIV TRIAL VALIDATES NOVEL DRUG MECHANISM
19/03/13	PRICE SENSITIVE	54.49KB	Share
BITHalf Yearly Report and Accounts
27/02/13	PRICE SENSITIVE	173.99KB	Share
BITAppendix 4C - quarterly
17/01/13	PRICE SENSITIVE	37.7KB	Share
BITBiotron Completes Clinical Stage of HIV Clinical Trial
14/12/12	PRICE SENSITIVE	49.29KB	Share

REFRESH

First 2 3 4 5

(20min delay)
Last 2.0¢		Change -0.001(4.76%)		Mkt cap ! $18.04M

Open	High	Low	Value	Volume
2.1¢	2.1¢	2.0¢	$12.00K	600.2K

Buyers (Bids)

No.	Vol.	Price($)
5	972631	1.9¢

Sellers (Offers)

Price($)	Vol.	No.
2.1¢	199783	1

View Market Depth

No.	Vol.	Price($)
5	972631	0.019
10	2364942	0.018
6	738000	0.017
11	1456225	0.016
4	635000	0.015

Price($)	Vol.	No.
0.021	199783	1
0.022	41868	2
0.023	506413	1
0.024	222185	3
0.025	600000	3

Last trade - 14.33pm 01/11/2024 (20 minute delay)


Last 2.0¢		Change -0.001 ( 4.76 %)
Open	High	Low	Volume
2.0¢	2.0¢	2.0¢	199442
Last updated 14.33pm 01/11/2024 ?

BIT (ASX) Chart

BIOTRON LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available